SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin enters into collaboration with Enzene Biosciences to launch Cetuximab

30 May 2023 Evaluate

Lupin has entered into strategic collaboration with Enzene Biosciences to launch Cetuximab in India, the first biosimilar developed for Cetuximab. This collaboration marks a significant milestone in expanding therapeutic options and fostering innovation in the critical area of treatment of head and neck cancer. Cetuximab has received approval from the Drug Controller General of India (DCGI) for its effectiveness in treating head and neck cancer, particularly Squamous Cell Carcinoma of the Head and Neck (SCCHN), making it a crucial solution for patients with recurrent locoregional or metastatic conditions. Cetuximab is available as a 100mg vial.

Head and neck cancer presents a significant public health challenge in India, with a staggering annual incidence of over 100,000 new cases. This malignancy affects critical regions of the head and neck, including the oral cavity, pharynx, larynx, and sinuses. The disease is often diagnosed at advanced stages, making effective treatment increasingly challenging. As a result, head and neck cancer carries a substantial burden, leading to significant difficulties in providing effective treatment and resulting in high mortality rates.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.


Lupin Share Price

2377.90 -81.85 (-3.33%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×